Stokes WA, et al. - This study sheds light on the therapeutic benefit of immunotherapy in combination with radiotherapy in patients with melanoma brain metastases (MBM). As per observations, immunotherapy + radiotherapy affords improved survival in this group of patients.

Methods

• Researchers queried National Cancer Database for patients with MBM and receiving brain radiotherapy.
• Based on the immunotherapy receipt, they classified the patients.
• They determined factors associated with survival via Multivariate Cox regression.

Results

• 185 patients received immunotherapy out of a total of 1287 patients.
• Younger age, academic facility, lower extracranial disease burden, stereotactic radiotherapy, chemotherapy, and immunotherapy were associated with improved survival.